(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of 422.38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.3%.
Zenas Biopharma's revenue in 2026 is $1,000,000.On average, 8 Wall Street analysts forecast ZBIO's revenue for 2026 to be $66,480,257, with the lowest ZBIO revenue forecast at $63,873,189, and the highest ZBIO revenue forecast at $68,435,559. On average, 8 Wall Street analysts forecast ZBIO's revenue for 2027 to be $3,850,836,325, with the lowest ZBIO revenue forecast at $1,760,292,935, and the highest ZBIO revenue forecast at $6,480,391,214.
In 2028, ZBIO is forecast to generate $9,622,039,616 in revenue, with the lowest revenue forecast at $5,670,700,785 and the highest revenue forecast at $20,325,361,068.